JP7149614B2 - ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 - Google Patents

ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Download PDF

Info

Publication number
JP7149614B2
JP7149614B2 JP2019553932A JP2019553932A JP7149614B2 JP 7149614 B2 JP7149614 B2 JP 7149614B2 JP 2019553932 A JP2019553932 A JP 2019553932A JP 2019553932 A JP2019553932 A JP 2019553932A JP 7149614 B2 JP7149614 B2 JP 7149614B2
Authority
JP
Japan
Prior art keywords
compound
quencher
alkyl
item
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513050A (ja
JP2020513050A5 (enExample
Inventor
マシュー エス． ボギョ，
マルテイン フェルドゥース，
レスリー オフォリ，
ニマリ ピー． ウィットハナ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2020513050A publication Critical patent/JP2020513050A/ja
Publication of JP2020513050A5 publication Critical patent/JP2020513050A5/ja
Application granted granted Critical
Publication of JP7149614B2 publication Critical patent/JP7149614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • C09B23/08—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines
    • C09B23/086—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups more than three >CH- groups, e.g. polycarbocyanines more than five >CH- groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019553932A 2017-03-30 2018-03-30 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤 Active JP7149614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478639P 2017-03-30 2017-03-30
US62/478,639 2017-03-30
PCT/US2018/025567 WO2018183960A1 (en) 2017-03-30 2018-03-30 Protease-activated contrast agents for in vivo imaging

Publications (3)

Publication Number Publication Date
JP2020513050A JP2020513050A (ja) 2020-04-30
JP2020513050A5 JP2020513050A5 (enExample) 2021-05-06
JP7149614B2 true JP7149614B2 (ja) 2022-10-07

Family

ID=63678348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553932A Active JP7149614B2 (ja) 2017-03-30 2018-03-30 ｉｎ ｖｉｖｏ画像化のためのプロテアーゼ活性化コントラスト剤

Country Status (6)

Country Link
US (2) US11828752B2 (enExample)
EP (1) EP3601261A4 (enExample)
JP (1) JP7149614B2 (enExample)
KR (1) KR102669535B1 (enExample)
CN (1) CN110678460A (enExample)
WO (1) WO2018183960A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406872B (zh) * 2015-01-22 2023-03-28 里兰斯坦福初级大学理事会 用于标记动物组织的化合物、组合物及其应用
WO2022203930A1 (en) * 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fluorogenic cyanine carbamates
CN116199662B (zh) * 2021-11-30 2024-10-11 中国科学院大连化学物理研究所 一种可见光和近红外光罗丹明荧光淬灭剂及其合成和应用
CN116199675B (zh) * 2021-11-30 2024-08-20 中国科学院大连化学物理研究所 一类罗丹明荧光淬灭剂及其合成和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519320A (ja) 2007-02-28 2010-06-03 サノフィ−アベンティス イメージングプローブ
WO2016118910A1 (en) 2015-01-22 2016-07-28 The Board Of Trustees Of The Leland Stanford Junior University Protease-activated contrast agents for in vivo imaging

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60888A (en) 1978-06-16 1984-07-31 Yeda Res & Dev Substrates and process for the quantitative assay of enzymes
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
AU2704395A (en) 1995-06-13 1997-01-09 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative di seases
US6544951B2 (en) 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US20020052323A1 (en) 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
GB0112868D0 (en) 2001-05-25 2001-07-18 Secr Defence Detection system
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
US20060148014A1 (en) 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
US8968700B2 (en) 2005-08-11 2015-03-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging of protease activity in live cells using activity based probes
CN101652149B (zh) 2007-02-28 2012-11-14 塞诺菲-安万特股份有限公司 成像探针
CA2695244A1 (en) 2007-08-03 2009-02-12 Sanofi-Aventis Caspase imaging probes
US20090214436A1 (en) 2008-02-18 2009-08-27 Washington University Dichromic fluorescent compounds
WO2009124265A1 (en) 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
US9155471B2 (en) 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
WO2012021800A2 (en) 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2012118715A2 (en) 2011-02-28 2012-09-07 The Board Of Trustees Of Leland Stanford Junior University Non-peptidic quenched fluorescent imaging probes
US8709830B2 (en) 2011-03-18 2014-04-29 Biotium, Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
WO2013036743A1 (en) 2011-09-09 2013-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Imaging agents for imaging protease activity and uses thereof
US20140180073A1 (en) 2012-12-24 2014-06-26 Anticancer, Inc. Portable digital imaging system for fluorescence-guided surgery
KR20160037834A (ko) 2013-03-14 2016-04-06 루미셀, 아이엔씨. 의료 이미징 장치 및 사용 방법
WO2014145257A2 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Activity-based probe compounds, compositions, and methods of use
WO2014171899A1 (en) 2013-04-19 2014-10-23 Agency For Science, Technology And Research Tunable fluorescence using cleavable linkers
US20170050988A1 (en) * 2013-11-25 2017-02-23 Sanofi Dotam derivatives for therapeutic use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519320A (ja) 2007-02-28 2010-06-03 サノフィ−アベンティス イメージングプローブ
WO2016118910A1 (en) 2015-01-22 2016-07-28 The Board Of Trustees Of The Leland Stanford Junior University Protease-activated contrast agents for in vivo imaging

Also Published As

Publication number Publication date
KR102669535B1 (ko) 2024-05-24
CN110678460A (zh) 2020-01-10
WO2018183960A1 (en) 2018-10-04
EP3601261A1 (en) 2020-02-05
JP2020513050A (ja) 2020-04-30
US20210109090A1 (en) 2021-04-15
KR20200002874A (ko) 2020-01-08
US20240077475A1 (en) 2024-03-07
US11828752B2 (en) 2023-11-28
EP3601261A4 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
JP7689753B2 (ja) 活性に基づくプローブの化合物、組成物、および使用方法
US12459972B2 (en) Protease-activated contrast agents for in vivo imaging
JP7720102B2 (ja) 活性ベースのプローブ化合物、組成物、および使用方法
US20240077475A1 (en) Protease-activated contrast agents for in vivo imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210326

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220824

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220916

R150 Certificate of patent or registration of utility model

Ref document number: 7149614

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250